Abstract:BACKGROUND:Hepatitis B virus (HBV) recurrence may result in hepatic insufficiency or dysfunction of liver grafts. This study was to reevaluate the preventive effect of lamivudine therapy pretransplant on HBV recurrence after liver transplantation with combined lamivudine and hepatitis B immunoglobulin (HBIG) as a prophylactic regimen. METHODS:This is a single-center, retrospective study of 122 liver transplant recipients operated on from January 2002 to September 2006 at our hospital. All subjects showed positive hepatitis B surface antigen (HBsAg) and HBV DNA in blood, without HBV mutation in YMDD at the time of liver transplantation. The protocol with combined lamivudine and HBIG for preventing HBV recurrence was used on the day of operation. The initial immunosuppression therapy was identical. After one year follow-up, the recipients were divided into 2 groups: patients without HBV recurrence (group I) and patients with HBV recurrence (group II). Preoperative lamivudine therapy and postoperative mycophenolate mofetil (MMF) and glucocorticoid therapy were analyzed using the Wilcoxon's test and Stepwise logistic regression method. RESULTS:In the HBV recurrence group, the duration of pre-transplant lamivudine administration was significantly longer than that in the without HBV recurrence group (Z=-4.424, P=0.000). The HBV recurrence rate was significantly higher in patients with preoperative lamivudine therapy than in patients without lamivudine therapy (X2=13.11, P=0.000); the risk of HBV recurrence increased by a 10.909-fold in patients with pre-transplant lamivudine therapy compared with that in patients without lamivudine therapy (OR=10.909; 95% CI for OR: 2.86-41.67). Seven (63.6%) of 11 HBV recurrence recipients had YMDD mutants. The duration of MMF or glucocorticoid was not different between the 2 groups (Z(MMF)=-1.453, P(MMF)=0.146; Z(Pre)=-0.795, P(Pre)=0.427). No significant difference was noted in the HBV recurrent rate in patients with MMF duration < or =6 and >6 months (X2=0.185, P=0.667), as it was in patients with prednisone therapy < or =3 and >3 months (X2=0.067, P=0.793). CONCLUSIONS:With the protocol of combined lamivudine and HBIG for preventing HBV recurrence in liver transplantation recipients, liver transplantation candidates with positive HBV DNA should not be subjected to preoperative administration of lamivudine. A high dose of HBIG during the ahepatic period and in the early stage of post-transplantation can fulfill the treatment target as a long-term lamivudine therapy before liver transplantation. Long-term preoperative lamivudine treatment may result in an earlier HBV mutation in YMDD and increase the HBV recurrence rate and risk in the first year after transplantation.

Clinical Study on the Combination of Telbivudine and HBIG to Prevent Hepatitis B Recurrence after Liver Transplantation

Effect of Lamivudine and Hepatitis B Immunoglobulin for Prevention of Recurrent Hepatitis B after Liver Transplantation

HBV Recurrence Lowered by Lamivudine/hbig Combination Therapy in Liver Transplant Patients: Ten-Year Experience

The Combination of Lamivudine and Hepatitis B Immune Globulin in the Prophylatic Treatment of HBsAg Positive Renal Transplant Receipts

INTRAMUSCLAR LOW-DOSE HEPATITIS B IMMUNE GLOBULIN COMBINED WITH LAMIVUDINE FOR PROPHYLAXIS AGAINST HEPATITIS B RECURRENCE AFTER LIVERTRANSPLANTATION

The correlation of HBV infection and HCMV reactive infection after liver transplantation

Impact of Human Leukocyte Antigen Matching on Hepatitis B Virus Recurrence after Liver Transplantation.

[17-year study on the curative effect of treatment to prevent the recurrence of hepatitis B in different risk groups after liver transplantation]

Prevention and Treatment of Hepatitis B Recurrence after Liver Transplantation.

Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis

Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.

Reevaluation of the Effect of Lamivudine Therapy Preoperative to Prevent Hbv Recurrence after Liver Transplantation

Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: A systematic review

Long-term prevention of virus recurrence among recipients with HBV active replication following liver transplantation

Lamivudine in prevention and treatment of recurrent HBV after liver transplantation.

Entecavir Combined with Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

The role of entecavir in preventing hepatitis B recurrence after liver transplantation

Clinical Analysis of Viral Hepatitis B Recurrence after Liver Transplantation for HBV-related Liver Diseases

An analysis of long term prophylaxis of virus recurrence with antiviral treatment in HBV infected liver transplant recipient patients

Intramuscular injection of hepatitis B immunoglobulin combined with lamivudine to prevent hepatitis B virus reinfection following liver transplantation: An analysis of 35 cases